The Company Developing More Time for Organ Transplantation

Imagine that someone you love finally receives the call. A donor organ is available. The surgery team is ready. Then weather, distance, testing, or a mismatch consumes the few hours the organ can remain viable.

A heart may have only about six hours outside the body. A liver may have about twelve. A kidney lasts longer, but the clock still limits matching, testing, transportation, surgery, and the number of organs that can be used.

More than 103,000 people are on the United States waiting list, while about 48,000 transplants were performed in 2024. Seventeen people die each day while waiting. Better organ supply is essential, but supply alone does not solve the time problem. Medicine also needs a way to pause biological damage after an organ leaves the donor.

Cooling slows metabolism. The colder an organ becomes, the less oxygen and energy it consumes. The problem is water. If ice crystals form, they can rupture cell membranes, damage blood vessels, and make the organ unusable.

One private company is assembling several preservation technologies around that problem. Its nearer-term method uses an isochoric chamber, a sealed and constant-volume system that changes the physics of freezing. By removing air and preventing the liquid volume from expanding, the chamber can suppress ice formation while an organ is held below zero.

The company is also working on vitrification. Instead of allowing water to crystallize into ice, carefully designed cryoprotectant mixtures and controlled cooling turn the tissue into a glass-like state. The company describes high-throughput searches for high-entropy cocktails intended to remain stable across a wide temperature range, followed by controlled rewarming.

Nature Biotechnology reports that viable pig kidneys were transplanted after 72 to 100 hours of isochoric preservation at about -4°C. A 2026 University of Minnesota conference program describes world-first pig-kidney transplants after several days of ice-free, cryoprotectant-free supercooling.

That matters because it tests the complete function, not merely whether tissue looks normal under a microscope. A preserved kidney had to be rewarmed, connected to a recipient, perfused with blood, and recover function.

The full methods, controls, sample size, durability, and peer-reviewed results remain the next source-lock. But moving from preserved tissue to a transplanted large-animal organ is a meaningful step toward clinical translation.

An organ bank could give doctors time to test function, match donors more precisely, plan surgery during staffed hours, use ground transport instead of emergency flights, and possibly coordinate immune-tolerance treatments. Longer preservation could also make genetically engineered or lab-grown organs easier to distribute.

The same physics may apply at several scales. Cells and engineered tissues could become reliable off-the-shelf products. Human tissue libraries could improve drug testing. Brain-tissue preservation could give researchers better living models for studying injury and neurodegeneration.

That last possibility needs a bright line. Preserving brain tissue is not the same as curing Alzheimer's disease, preserving a person, or restoring memory after whole-brain storage. A 2026 independent study reported functional recovery in adult mouse hippocampal tissue after vitrification, which strengthens the field's scientific plausibility. It is not a result from the company in this issue.

Today, a healthy donated organ can become unusable simply because time runs out. Families wait while doctors race distance, weather, testing, and a biological clock measured in hours.

The company in this issue is trying to change that clock.

Its technology has reportedly kept pig kidneys viable for several days before transplantation. If that result holds up and eventually translates to people, doctors could gain more time to match organs, test them, transport them safely, and reach patients who might otherwise never receive one.

The opportunity may not stop with transplantation. The same preservation physics could eventually support engineered tissues, cell therapies, organ banking, and better living models of brain disease. None of those outcomes is assured, but the platform is addressing a clear and enormously consequential constraint: living tissue begins deteriorating before medicine has enough time to use it.

Transplantation is the first identifiable market. Organ failure already produces enormous costs through emergency transportation, intensive surgery, discarded organs, complications, and years of follow-up care.

A successful preservation platform could potentially serve transplant centers, organ-procurement networks, biotechnology manufacturers, research biobanks, and regenerative-medicine supply chains. The company reports $26 million in financing and grants, but its current valuation and security terms are not public.

That leaves two very different questions:

EverLife's framework answers the first question strongly. Under a clearly labeled hypothetical-access scenario, the company scores 3.90 and reaches EverLife's Research Scout threshold.

This is not merely an idea described in a pitch deck. The public research file includes a reported multi-day pig-kidney preservation result, several complementary preservation technologies, and a team combining transplant experience, cryobiology, and thermodynamics.

But the most valuable details are below the paywall:

You do not need to wait until a technology becomes widely known to understand why it matters. You need a disciplined way to recognize the evidence while the field is still developing.

Join EverLife Premium to reveal the company and open the complete research file.